Mats Christian Hojbjerg Lassen, B.M., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ventricular Dysfunction, Left | 10 | 2023 | 2118 | 2.470 |
Why?
|
Stroke Volume | 18 | 2024 | 5496 | 1.760 |
Why?
|
Ventricular Function, Left | 22 | 2024 | 3879 | 1.650 |
Why?
|
Mitral Valve | 6 | 2021 | 1465 | 1.650 |
Why?
|
Echocardiography | 20 | 2024 | 4989 | 1.500 |
Why?
|
Diastole | 7 | 2023 | 782 | 1.370 |
Why?
|
Heart Failure | 18 | 2024 | 11670 | 1.230 |
Why?
|
Influenza Vaccines | 3 | 2024 | 768 | 1.210 |
Why?
|
Influenza, Human | 4 | 2024 | 1521 | 1.030 |
Why?
|
Denmark | 9 | 2024 | 771 | 0.890 |
Why?
|
Ventricular Dysfunction, Right | 3 | 2024 | 628 | 0.810 |
Why?
|
Heart Atria | 8 | 2024 | 1345 | 0.790 |
Why?
|
Blood Flow Velocity | 3 | 2020 | 1371 | 0.780 |
Why?
|
Atrial Function, Left | 6 | 2024 | 185 | 0.760 |
Why?
|
Heart Diseases | 3 | 2024 | 2781 | 0.740 |
Why?
|
Biphenyl Compounds | 2 | 2024 | 1007 | 0.690 |
Why?
|
Glucosides | 1 | 2024 | 512 | 0.660 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2024 | 12148 | 0.640 |
Why?
|
Drug Combinations | 2 | 2024 | 2048 | 0.640 |
Why?
|
Angiotensin Receptor Antagonists | 2 | 2024 | 1039 | 0.610 |
Why?
|
Polycystic Kidney, Autosomal Dominant | 1 | 2019 | 166 | 0.610 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2023 | 3415 | 0.590 |
Why?
|
Hypoglycemic Agents | 3 | 2024 | 3085 | 0.570 |
Why?
|
Echocardiography, Doppler | 3 | 2020 | 897 | 0.570 |
Why?
|
Benzhydryl Compounds | 1 | 2024 | 916 | 0.570 |
Why?
|
Diabetes Mellitus | 2 | 2024 | 5841 | 0.500 |
Why?
|
Myocardium | 4 | 2024 | 4725 | 0.470 |
Why?
|
Myocardial Contraction | 1 | 2019 | 1515 | 0.460 |
Why?
|
Pneumonia | 2 | 2024 | 2143 | 0.430 |
Why?
|
Middle Aged | 42 | 2024 | 220920 | 0.430 |
Why?
|
Medication Adherence | 1 | 2024 | 2176 | 0.410 |
Why?
|
Atrial Fibrillation | 7 | 2024 | 5127 | 0.390 |
Why?
|
Predictive Value of Tests | 13 | 2024 | 15266 | 0.390 |
Why?
|
Prospective Studies | 20 | 2024 | 54426 | 0.390 |
Why?
|
Aged | 34 | 2024 | 169310 | 0.370 |
Why?
|
Cardiovascular Diseases | 6 | 2023 | 15501 | 0.350 |
Why?
|
Acute Coronary Syndrome | 2 | 2024 | 2190 | 0.350 |
Why?
|
Male | 48 | 2024 | 360842 | 0.350 |
Why?
|
Systole | 5 | 2023 | 936 | 0.340 |
Why?
|
Myocardial Infarction | 5 | 2023 | 11461 | 0.320 |
Why?
|
Kidney Failure, Chronic | 1 | 2021 | 2472 | 0.320 |
Why?
|
Female | 46 | 2024 | 392686 | 0.320 |
Why?
|
Echocardiography, Three-Dimensional | 2 | 2024 | 607 | 0.310 |
Why?
|
Alcohol Drinking | 1 | 2021 | 4028 | 0.300 |
Why?
|
Registries | 1 | 2024 | 8224 | 0.300 |
Why?
|
Prognosis | 14 | 2024 | 29629 | 0.300 |
Why?
|
Humans | 64 | 2024 | 761572 | 0.300 |
Why?
|
Kidney Transplantation | 1 | 2021 | 4235 | 0.270 |
Why?
|
Hospitalization | 5 | 2024 | 10721 | 0.260 |
Why?
|
Reference Values | 5 | 2024 | 4920 | 0.250 |
Why?
|
Coronary Stenosis | 2 | 2020 | 794 | 0.230 |
Why?
|
Ventricular Function, Right | 3 | 2024 | 617 | 0.230 |
Why?
|
Ventricular Remodeling | 2 | 2021 | 1267 | 0.220 |
Why?
|
Cohort Studies | 9 | 2024 | 41493 | 0.210 |
Why?
|
Government | 1 | 2023 | 161 | 0.210 |
Why?
|
Hypertension | 4 | 2024 | 8540 | 0.210 |
Why?
|
Vaccination | 3 | 2023 | 3384 | 0.210 |
Why?
|
Coronary Artery Disease | 4 | 2024 | 6403 | 0.200 |
Why?
|
Adult | 20 | 2024 | 221203 | 0.190 |
Why?
|
Tetrazoles | 2 | 2024 | 909 | 0.190 |
Why?
|
Risk Factors | 13 | 2024 | 74213 | 0.180 |
Why?
|
Longitudinal Studies | 6 | 2024 | 14607 | 0.180 |
Why?
|
Particle Size | 1 | 2024 | 1648 | 0.170 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2024 | 2243 | 0.170 |
Why?
|
Echocardiography, Doppler, Pulsed | 1 | 2019 | 69 | 0.170 |
Why?
|
Venous Thromboembolism | 2 | 2024 | 1866 | 0.170 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2024 | 3204 | 0.150 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 2019 | 231 | 0.150 |
Why?
|
Heart Failure, Systolic | 1 | 2019 | 135 | 0.140 |
Why?
|
Estradiol | 1 | 2024 | 1937 | 0.140 |
Why?
|
Hydroxychloroquine | 1 | 2021 | 426 | 0.140 |
Why?
|
Breast Neoplasms | 1 | 2024 | 21017 | 0.130 |
Why?
|
Glomerular Filtration Rate | 1 | 2024 | 2177 | 0.130 |
Why?
|
Adrenal Cortex Hormones | 1 | 2024 | 1881 | 0.130 |
Why?
|
Cystic Fibrosis | 1 | 2024 | 1285 | 0.120 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2020 | 575 | 0.120 |
Why?
|
Coronary Angiography | 3 | 2024 | 4471 | 0.120 |
Why?
|
Mitral Valve Insufficiency | 1 | 2024 | 1400 | 0.120 |
Why?
|
Recurrence | 2 | 2024 | 8466 | 0.120 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2022 | 1723 | 0.110 |
Why?
|
Morbidity | 1 | 2019 | 1750 | 0.110 |
Why?
|
Occupational Diseases | 1 | 2021 | 1490 | 0.110 |
Why?
|
Myocardial Ischemia | 1 | 2023 | 2113 | 0.100 |
Why?
|
Coronary Artery Bypass | 1 | 2021 | 2188 | 0.100 |
Why?
|
Treatment Outcome | 5 | 2024 | 64684 | 0.100 |
Why?
|
Retrospective Studies | 6 | 2024 | 80646 | 0.090 |
Why?
|
Occupational Exposure | 1 | 2021 | 1813 | 0.090 |
Why?
|
Risk Assessment | 8 | 2024 | 23996 | 0.090 |
Why?
|
Sex Characteristics | 1 | 2021 | 2639 | 0.090 |
Why?
|
Double-Blind Method | 1 | 2024 | 12341 | 0.090 |
Why?
|
Regression Analysis | 1 | 2019 | 6344 | 0.080 |
Why?
|
Sex Factors | 2 | 2024 | 10553 | 0.080 |
Why?
|
Blood Glucose | 1 | 2024 | 6391 | 0.080 |
Why?
|
Aged, 80 and over | 6 | 2024 | 58986 | 0.080 |
Why?
|
Age Factors | 2 | 2024 | 18398 | 0.080 |
Why?
|
Atherosclerosis | 1 | 2024 | 3408 | 0.070 |
Why?
|
Mortality | 1 | 2019 | 2901 | 0.070 |
Why?
|
Multivariate Analysis | 1 | 2021 | 12059 | 0.070 |
Why?
|
Disease Progression | 1 | 2024 | 13510 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10212 | 0.070 |
Why?
|
Time Factors | 4 | 2024 | 39970 | 0.070 |
Why?
|
Heart Ventricles | 3 | 2024 | 3807 | 0.070 |
Why?
|
Survival Analysis | 1 | 2019 | 10090 | 0.070 |
Why?
|
Catheter Ablation | 1 | 2020 | 2751 | 0.070 |
Why?
|
Logistic Models | 1 | 2021 | 13255 | 0.070 |
Why?
|
Case-Control Studies | 2 | 2024 | 22176 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2024 | 39107 | 0.060 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26127 | 0.060 |
Why?
|
Incidence | 4 | 2024 | 21355 | 0.060 |
Why?
|
Metered Dose Inhalers | 1 | 2024 | 25 | 0.060 |
Why?
|
Administration, Intravaginal | 1 | 2024 | 150 | 0.060 |
Why?
|
Smoking | 1 | 2021 | 9053 | 0.060 |
Why?
|
Cause of Death | 2 | 2024 | 3683 | 0.050 |
Why?
|
Republic of Korea | 1 | 2024 | 590 | 0.050 |
Why?
|
Prevalence | 3 | 2024 | 15732 | 0.050 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 450 | 0.050 |
Why?
|
Administration, Inhalation | 1 | 2024 | 1157 | 0.050 |
Why?
|
Lifting | 1 | 2021 | 55 | 0.050 |
Why?
|
Ultrasonography, Doppler | 1 | 2023 | 462 | 0.040 |
Why?
|
Lung | 3 | 2024 | 10002 | 0.040 |
Why?
|
Troponin | 1 | 2022 | 502 | 0.040 |
Why?
|
Tomography | 1 | 2020 | 411 | 0.040 |
Why?
|
Stroke | 1 | 2020 | 9758 | 0.040 |
Why?
|
Ultrasonography | 2 | 2021 | 5972 | 0.040 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2022 | 851 | 0.040 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1516 | 0.030 |
Why?
|
ROC Curve | 1 | 2024 | 3579 | 0.030 |
Why?
|
Netherlands | 1 | 2020 | 2221 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2024 | 15843 | 0.030 |
Why?
|
Population Surveillance | 1 | 2024 | 2598 | 0.030 |
Why?
|
Adaptation, Physiological | 1 | 2020 | 1301 | 0.030 |
Why?
|
Oxygen | 1 | 2022 | 4227 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2022 | 3826 | 0.020 |
Why?
|
Calcium | 1 | 2024 | 5722 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2022 | 5112 | 0.020 |
Why?
|
Acute Disease | 1 | 2020 | 7237 | 0.020 |
Why?
|
Heart | 1 | 2021 | 4404 | 0.020 |
Why?
|
Blood Pressure | 1 | 2023 | 8481 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12463 | 0.020 |
Why?
|
Young Adult | 1 | 2022 | 59255 | 0.010 |
Why?
|